Abel Hall LLC
OVID icon

Abel Hall LLC’s Ovid Therapeutics OVID Stock Holding History

Abel Hall LLC’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$71K Buy
28,499
+175
+0.6% +$458 0.01% 808
2026
Q2 		$76.2K Sell
28,324
-2,865
-9% -$7.39K 0.01% 867
2026
Q1 		$69.2K Sell
31,189
-238
-0.8% -$426 0.01% 718
2025
Q4 		$51.2K Sell
31,427
-921
-3% -$1.42K 0.01% 658
2025
Q3 		$42.1K Hold
32,348
– – 0.02% 302
2025
Q2 		$10.7K Buy
32,348
+22,110
+216% +$6.66K ﹤0.01% 282
2025
Q1 		$3.19K Buy
+10,238
New +$6.3K ﹤0.01% 201

Other funds holding OVID

Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Total Clarity Wealth Management
Total Clarity Wealth Management St. Charles, Illinois $518M AUM 17.26% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Benin Management Corp
Benin Management Corp Wilton, Connecticut $517M AUM 21.33% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Empirical Wealth Management
Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return
Aaron Wealth Advisors
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Abel Hall LLC's OVID Position: Q3 2026 in Review

Abel Hall LLC increased its Ovid Therapeutics (OVID) stake by 0.62% in Q3 2026, buying an estimated $458 and bringing the position to 28,499 shares worth $71K. The position accounts for 0.01% of the portfolio, ranked #808.

Abel Hall LLC first reported a position in OVID in Q1 2025 and has held it in 7 quarters since. The position peaked at $76.2K in Q2 2026. 18 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • Abel Hall LLC held 28,499 shares of Ovid Therapeutics worth $71K as of Q3 2026.
  • Abel Hall LLC bought 175 Ovid Therapeutics shares in Q3 2026, an estimated $458.
  • Ovid Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q3 2026, its #808 holding.
  • Abel Hall LLC first reported a position in Ovid Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Abel Hall LLC's Ovid Therapeutics position peaked at $76.2K in Q2 2026.
  • 18 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.